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HER2-targeted therapies have radically changed the prognosis of HER2-positive breast 
cancer over the last few years. However, resistance to these therapies has been a 
constant, leading to treatment-failure and new tumor progression. Recently, the 
kinase-impaired HER3 emerged as a pivotal player in oncogenic signaling, with an 
important role in both non-treated progression and treatment response. HER2/HER3 
dimerization is required for full signaling potential and constitutes the key oncogenic 
unit. Also, when inhibiting PI3K/AKT pathway (as with anti-HER2 drugs) feedback 
mechanisms lead to a rebound in HER3 activity, which is one of the main roads to 
resistance. As current strategies to treat HER2-positive breast cancer are unable to 
inhibit this feedback response, two great promises emerged: the combination of 
targeted-therapies and drugs targeting HER3. In this article HER2 and HER3-targeted 
drugs and possible combinations between them, as well as the biomarkers to predict 
and monitor these drugs effect, are reviewed.
Keywords:  antineoplastic drug resistance • biomarkers • breast cancer • erbB-2 receptor 
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Breast cancer (BC) is the most common can-
cer diagnosis and the main cause of cancer-
related death in women worldwide [1]. HER2 
is overexpressed in 10–34% of all breast 
cancers and is strongly associated with a 
lower time to disease relapse and overall sur-
vival in the absence of treatment [2,3]. Upon 
understanding its special biologic behavior, 
HER2-driven BC started to be classified as 
a phenotypically distinct BC subtype [4]. In 
1998, a decade after linking HER2 positivity 
to adverse outcome, the approval of trastu-
zumab (the first HER2-targeted therapy) 
for the treatment of metastatic breast cancer 
(MBC) significantly improved BC progno-
sis [5]. Nowadays, new treatments targeting 
HER2 in the neoadjuvant, adjuvant and met-
astatic settings have significantly improved 
the panorama for BC patients.
Despite the progress achieved with HER2-
targeted therapy, acquired resistance has 
revealed to be a difficult problem to over-
come. In metastatic disease, the response to 
all of the approved therapies occurs only for 
a limited period of time after which tumor 
progression is again observed [6]. To continue 
the path of success achieved with HER2-
targeted therapy understanding the network 
in which HER2 is integrated and discovering 
more effective treatment options is of utmost 
importance, especially in the metastatic set-
ting. Thus, in this paper, the role played by 
ErbB family receptors in HER2-positive 
MBC and the strategies to optimize these 
cancers’ treatment, as well as the molecular 
markers to guide and monitor these therapies, 
are reviewed.
ErbB family
Human EGFR family, or ErbB family, con-
sists of four transmembrane tyrosine kinases: 
HER1 or EGFR, HER2, HER3 and HER4. 
They are encoded, respectively, by the ERBB1, 
ERBB2, ERBB3 and ERBB4 genes. These 
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receptors are composed of four extracellular domains 
(I, II, III and IV), a transmembrane portion, a tyrosine 
kinase domain and a carboxyterminal tail containing 
tyrosine residues and docking sites for intracellular sig-
naling molecules. Extracellular domains I and III are 
responsible for ligand binding and domains II and IV 
participate in dimer formation [7].
When inactive, these receptors exist as monomers 
in a tethered conformation that blocks the dimeriza-
tion arm (included in domain II). Ligand-binding to 
domains I and III induces a conformational change 
that exposes the dimerization arm, allowing homo- 
or heterodimerization. The activated kinase domains 
then bind asymmetrically (ones carboxyterminal por-
tion binds with others amino-terminal portion) and 
trans-phosphorylate the tyrosine residues in the car-
boxyterminal tails, creating docking sites for phos-
photyrosine-binding proteins (such as Grb2, Shc and 
PLCγ). This process activates downstream pathways 
as the PI3K/AKT, Ras/Raf/MEK/MAPK and PLC-γ 
pathway [7]. The first has an important role in cell 
survival and the second and third ones mediate cell 
proliferation (Figure 1). These receptors participate in 
normal cell growth and development in several tissues, 
however, when overexpressed, this family is responsi-
ble for unregulated cell division, apoptosis, migration, 
adhesion and differentiation: all processes leading to 
tumorigenesis [8].
Despite sharing a common structure, there are some 
differences between the four receptors. The extracel-
lular domain of HER2 has very unique characteristics: 
it is unable to bind a ligand or to assume a tethered 
configuration and, in addition, it has electronegative 
sequences in domain II. This makes it permanently 
available for dimerization with other receptors but 
unable to form homodimers due to electrostatic repulse 
[10]. Nevertheless, when overexpressed, this receptor 
forms ligand-independent functional homodimers 
[11]. HER2 is the preferred dimerization partner for all 
other receptors [12].
HER3 receptor can bind extracellular ligands and 
initiate a signaling transduction cascade (being its 
main ligand HRG) but it is described as having no 
kinase activity. Recent studies suggest that the kinase 
ability of HER3 is impaired, rather than inactive [13], 
however, more studies are needed to clarify this aspect. 
Once again, homodimers of this receptor are appar-
ently nonfunctional [13]. HER3 presents six and HER4 
one direct binding site for p85 subunit of PI3K, whereas 
HER1 and HER2 only interact with this protein indi-
rectly. This makes dimers containing HER3 the ones 
capable of the strongest activation of the PI3K/AKT 
pathway [9]. The combination of the special features 
of HER2 and HER3 receptors mentioned are thought 
to be the reason why HER2/HER3 dimer is the most 
potent partnership regarding ligand-induced tyrosine 
phosphorylation and mitogenic signaling [14,15].
In HER2/HER3 dimers, HER3 phosphorylation is 
accomplished by HER2 kinase, however, how HER2 
tyrosine residues are phosphorylated is not well estab-
lished. A recent study suggests that HER2/HER3 
heterodimers with a side-by-side orientation allow 
HER2 receptors to phosphorylate one another (a pro-
cess termed proxy phosphorylation). Other high-order 
interactions among ErbB receptors have been hypoth-
esized, hence this is a subject that requires further 
investigation [16].
ErbB family in HER2-positive breast cancer
HER2 positivity occurs mainly due to ERBB2 gene 
amplification [4] but it can also occur as a result of 
transcriptional deregulation, leading to overexpression 
of the receptor [17]. HER2-activating mutations have 
been recently described as an alternative mechanism, 
but the impact of this fact is still unclear [17]. HER2 
overexpression bias dimer formation toward HER2-
containing dimers. Although overexpressed HER2 
is able to homodimerize, heterodimers are formed 
preferentially and constitute stronger signaling com-
plexes. These heterodimers can be formed in a ligand-
dependent or ligand-independent way [8]. In HER2-
driven BC, HER2 overexpression is an early event in 
neoplastic transformation [18] and is generally retained 
when tumor progresses and metastases are formed [4]. 
However, the vast interdependence between the ErbB 
family receptors highlights the crucial role of HER2 
interactions with other ErbB receptors in neoplastic 
progression.
HER1 or HER2 overexpression is well established 
as predictive of decreased survival in invasive BC. 
More recently, HER3 overexpression was proved to 
decrease BC-specific survival independently of other 
prognostic factors [19]. It was also shown that HER3 
expression in HER2-positive invasive BC is correlated 
with a significantly lower disease-free survival [20].
As for HER4, its role remains the most controver-
sial. HER4 activity in BC cells has been linked to cel-
lular responses as growth inhibition, differentiation, 
apoptosis and cell proliferation, being associated with 
both favorable and worse prognosis [21,22]. Recently, a 
unique property of HER4 has been suggested to under-
pin this controversial role: the formation of a soluble 
intracellular domain (ICD) which is pointed as the 
critical effector of HER4 signaling [22,23]. The local-
ization of this ICD was found to determine the type 
of signaling response: while a mitochondrial localiza-
tion leads to an apoptotic response, a nuclear translo-
cation induces the ICD to act as an estrogen response 
www.futuremedicine.com 259
Figure 1. ErbB family receptors and ErbB signaling network. Only HER2/HER2, HER3/HER2 and HER1/HER2 dimers are represented 
due to their significance in HER2-driven breast cancer. Despite HER4 not being represented it shares the molecular structure of 
HER1–3. The four extracellular domains are represented as I–IV. Despite not being the exclusive ligands of HER1 and HER3, EGF and 
HRG are the only ligands shown as they are, respectively, HER1 and HER3 main activators. Most arrows portray processes that require 
several steps. For simplicity, only PI3K/AKT, RAS/RAF/MEK/MAPK and PLCγ/PKC pathways and their main signaling outcomes are 
shown. Proteins that directly bind phosphotyrosine residues are represented in light pink while subsequently activated proteins are 
represented in dark pink. HER3 tyrosine kinase domain is marked with a cross since it is kinase impaired. HER2 ligand binding sites are 
also associated with a cross since no ligand is known for this receptor. Note that only HER3 is able to bind PI3K p85 subunit (evidenced 
in the figure) and directly activate PI3K. HER1 and HER2 need other messenger proteins to indirectly activate this protein [7,9]. This 
figure is not drawn to scale. 
Please see color figure at www.futuremedicine.com/doi/pdf/10.2217/pgs.14.133
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element and to mediate proproliferative transcriptional 
activity [23]. The localization of the ICD is influenced 
by the type of cytoplasmic domain (ICD CYT-1 or 
CYT-2, formed by alternative splicing of HER4 pre-
mRNA) [22] and by estrogen receptor-induced signal-
ing [23]. As cycles of estrogen and progesterone during 
a woman’s life lead to chromatin rearrangements, the 
nuclear ICD has different transcriptional potential in 
parous versus nonparous women [24]. This last group 
of women is more likely to present a BC cell prolifera-
tion response [24]. Thus, the activity of HER4 contain-
ing heterodimers, as in HER2-driven breast tumors, is 
hypothesized to lead to a better outcome in parous or 
lactating hosts when compared with nonparous women 
[24]. Even taking in account these different responses 
according to ICD localization the most accepted vision 
is that HER4-expressing tumors have an overall bet-
ter prognosis, presenting a slight distinction among 
them: the ones expressing nuclear HER4 have a worse 
prognosis compared with the ones with membrane or 
cytoplasmic HER4 [21].
Comprehending ErbB signaling network is crucial 
for understanding major mechanisms leading to can-
cer progression and discovering new potential therapy 
targets. In this context, and since HER4’s impact on 
survival is still under discussion, HER1 and HER3 
were the most studied as HER2 coreceptors. It was 
shown that when HER2 is overexpressed, HER3 
cooperates with it, enhancing its neoplastic transfor-
mation potential [25]. Two essays revealed that loss of 
functional HER3 in HER2-overexpressing BC cells 
has similar impact to the loss of HER2 function in 
cell proliferation [26,27]; on the contrary, HER1 knock-
down has no significant biological relevance, whereby 
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it appears to be dispensable for proliferation [26]. In one 
of those studies the antiproliferative effect after HER3 
function loss was reported in cell lines that expressed 
HER1 and HER4. This suggests that HER3 is essen-
tial for proliferation on HER2-driven BC and that nei-
ther HER1 nor HER4 can replace HER3 as HER2’s 
partner [27]. In the other essay, phosphorylated HER3 
was significantly higher in HER2-overexpressing BC 
tissues when compared with HER2-negative ones. 
Once again, this did not happen with HER1, sug-
gesting that HER3 activity is important [26]. HER3 
knockdown in HER2-positive cell lines also proved 
to inhibit growth in three-dimensional culture and to 
lead to rapid tumor regression in vivo [26]. In addition 
to this role as enhancer of HER2-induced progression, 
it was recently shown that HER3 also has a prominent 
role in the preneoplastic changes of breast epithelial 
cells and tumor formation, proving a more extensive 
time influence in HER2-positive breast cancers [28].
It is thought that what underpins HER3’s special role 
is its capacity to directly activate the PI3K/AKT path-
way. This is supported by the fact that a constitutively 
active AKT protein completely rescues the antiprolifer-
ative effect induced by the loss of HER2 and HER3 sig-
naling [27]. It was shown that HER3-PI3K signaling is 
dispensable for HER2-driven tumorigenesis as HER2 
and HER1 proven to be able to independently activate 
PI3K and rescue the tumorigenic response [29]. Never-
theless, the total absence of HER3 expression deeply 
affects tumor progression, suggesting that HER3 also 
has important PI3K-independent functions [29]. It is 
currently accepted that in HER2-overexpressing BC, 
HER2/HER3 dimerization is required for full signal-
ing and carcinogenic potential. These data suggest that 
HER2/HER3 is the key oncogenic unit [26,27].
Targeting HER family
As mentioned above, this is a four-member family with 
multiple-domain receptors, which enables several tar-
geting strategies. The two main strategies used to tar-
get these receptors are monoclonal antibodies (mAbs) 
that bind to the receptor’s extracellular region and 
small-molecule tyrosine kinase inhibitors (TKIs) that 
block signal transduction (Figure 2) [30]. The first strat-
egy attempted was the inhibition of HER2 with the 
mAb trastuzumab, an antibody that binds domain IV 
of the extracellular part of HER2 [5]. Since then, other 
options to inhibit this receptor were approved such 
as other anti-HER2 mAbs, a TKI that inhibits both 
HER2’s and HER1’s kinases activity and strategies 
that double-target HER2 at different sites. Despite the 
progress achieved, intrinsic and acquired resistances 
are a significant problem. Intrinsic, primary or de novo 
resistance defines a status of nonmeasurable response to 
a drug, in other words, apparent lack of drug activity. 
Acquired resistance is treatment-induced and defines 
the mechanism by which tumors that once had a favor-
able drug response stopped responding [31]. Hence, this 
resistance issues leave much room for improvement.
It is crucial to keep in mind that we are facing an 
interdependent network and not an isolated over-
expressed receptor. The disruption of an axis integrated 
in an interconnected network like this one potentially 
leads to compensatory mechanisms [32]. Thereby, treat-
ment-induced resistance is not a fixed problem; it is a 
dynamic response to a specific blockage that is different 
according to the blocked target.
When trastuzumab is used as treatment, there are 
several mechanisms described that may account for 
drug resistance: altered antibody-receptor inter action, 
cross-talk between HER2 and other receptors (like 
ErbB receptors and insulin-like growth factor 1 recep-
tor – IGF1R) and modulation of the activity of intra-
cellular signaling proteins [31]. When the choice is to 
target HER2 and HER1 kinases, new mechanisms 
are blamed for treatment-induced resistance. It was 
shown that lapatinib, the only TKI approved, is only 
capable of an incomplete inhibition of HER2 kinase. 
This allows HER3 trans-phosphorylation to occur and 
restores signaling activity sufficiently enough to evade 
the proapoptotic effect of this drug. This suggests that 
complete inactivation of kinase activity is needed to 
overcome this problem. However, a clinically viable 
drug with this feature is not available [33,34].
It soon became clear that the ErbB family-mediated 
signaling was more resilient than initially thought and 
that avoiding the acquisition of resistance would require 
further study. Clinical trials evidenced that combined 
anti-HER2 therapies were superior to single-agent 
strategies and that drugs targeting different domains 
of the HER2 receptor have a synergistic effect when 
combined [35]. Hence, dual HER2-targeting strategies 
became a great promise to overcome resistance [36]. In 
fact, a combination of trastuzumab and pertuzumab 
– a mAb with a mechanism of action complementary 
to trastuzumab – proved to improve HER2-positive 
MBC outcome when compared with trastuzumab 
alone [37]. This successful double-targeting scheme 
proved the suspicion about the great potential of dual 
HER2-targeted approaches.
When further assessing the mechanisms under-
pinning treatment response and acquired resistance, 
HER3 emerged as a key receptor. It was shown that 
when directly or indirectly inhibiting PI3K/AKT 
pathway, a negative feedback response leads to a mul-
titude of redundant mechanisms to preserve tumori-
genic signaling: among them, an increased transcrip-
tion of receptors like the HER3 receptor [33,34,38,39] and 
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Figure 2. Drugs targeting HER2 and/or HER3. There are two main groups of drugs represented: monoclonal antibodies targeting 
the extracellular domains and tyrosine kinase inhibitors that bind to the receptor kinases in their intracellular portions. There are no 
monoclonal antibodies targeting the ligand-binding domains of HER2 once that no ligand is known for this receptor. There are no 
tyrosine kinase inhibitors targeting HER3 considering that its kinase is impaired. In its monomeric state, HER2 presents in an extended 
conformation. On the contrary, HER3 (as HER1 and HER4) assumes a tethered conformation, where its domains II and IV contact, 
maintaining the dimerization arm unavailable [7]. This figure is not drawn to scale. 
T-DM1: Ado-trastuzumab emtansine.
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the modulation of HER3 localization (locating it in 
the plasma membrane) [33]. This allows an increased 
phosphorylation of HER3. Also, when TKIs are used 
to inhibit this pathway, the protein tyrosine phospha-
tases activity is diminished and the dephosphorylation 
rate of this receptor is reduced [33]. These mechanisms 
all contribute to a rebound in HER3 activity, ampli-
fication of PI3K/AKT signaling and acquisition of 
resistance [33,34,38,39]. Evidence emerged that even the 
dual blockade of HER2 couldn’t eliminate HER3 
compensatory up-regulation and that drugs target-
ing HER3 could enhance the power of dual HER2-
targeted approaches [40]. As evidenced in this paper, 
HER3 is a pivotal player in oncogenic signaling and it 
has an important role in both nontreated progression 
and treatment response. Thus, interest in anti-HER3 
therapies is being raised and new drugs targeting this 
receptor are being tested.
The ultimate goal in HER-directed therapies is 
the complete inhibition of downstream signaling to 
avoid or at least delay the acquisition of resistance. To 
achieve this aim, the combination of targeted therapies 
has increasingly been pointed out as the road to follow 
[36]. Despite the existence of other possible targets in 
this network and due to the crucial role of HER2 and 
HER3 in neoplastic transformation, a particular focus 
will be given to drugs that interfere with HER2 and/or 
HER3 activity.
Biomarkers
Almost as important as developing targeted agents is 
the identification of biomarkers to allow treatment-
decision and clinical application of the drug. Also, dur-
ing treatment, biomarkers are tools of utmost impor-
tance for prediction and monitoring the drug’s effect. 
At this point, HER2 overexpression as defined by 
ERBB2 amplification (determined by FISH) or HER2 
protein overexpression (determined by immunohisto-
chemistry) is the only biomarker approved for HER2-
targeted therapy [41]. PIK3CA is an oncogene frequently 
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mutated in BC [42] and oncogenic-PIK3CA mutations 
are emerging as a potential marker of worse prognosis 
in patients being treated with anti-HER2 drugs, except 
for the ones being treated with T-DM1, as documented 
in the NeoSphere, CLEOPATRA and EMILIA bio-
marker analyses [43–45]. p95HER2 expression (a trun-
cated form of the HER2 receptor that lacks the extra-
cellular domain) has been shown to be associated with 
intrinsic resistance to trastuzumab in the metastatic 
setting [46]. Nuclear imaging methods like PET (posi-
tron emission tomography) and SPECT (single photon 
emission computed tomography) are being tested for 
the detection of HER2-positive lesions [47,48]. These 
techniques allow a noninvasive way to assess metasta-
ses’ HER2 status, which is particularly relevant for the 
metastases that are not accessible for biopsy. Moreover, 
as sampling errors cannot be ruled out with repeated 
biopsies, this provides a method to exclude sampling 
error [47]. Blood-based markers require samples that 
are easier to obtain and are also being evaluated as pre-
dictors of treatment response. Several blood biomark-
ers are currently being tested: circulating HER2-free 
DNA [49] and PIK3CA-activating mutations [42].
There are no current biomarkers to predict HER3-
targeted response. As in most HER3-driven tumors 
HER3 is not mutated or amplified it is much more dif-
ficult to define this receptor as responsible for tumor 
progression. So far, high levels of ERBB3 mRNA 
in patients with HER2-positive MBC treated with 
trastuzumab, pertuzumab and docetaxel were signifi-
cantly associated with better prognosis in CLEOPA-
TRA biomarker analyses [44]. However, no significant 
association was found in other studies [43,50]. HER3 
protein expression has also been evaluated: no cor-
relation was found regarding neoplasias treated with 
association of anti-HER2 drugs [43,44,50] but high lev-
els of HER3 were significantly associated with poor 
prognosis on MBCs treated with trastuzumab [46]. It 
was also shown that an anti-HER3 antibody was more 
effective in cancers with ligand-dependent activation 
of HER3. This suggests that expression of HER3 
ligands could be a marker for successful HER3 tar-
geting [51]. Trans-phosphorylated HER3 (or pHER3) 
has been referred as one of the most promising bio-
markers [33,40,52]. Receptor phosphorylation is a marker 
for HER3-mediated cellular activation, contrary to 
the presence of markers such as HER3 ligands, which 
represent an indirect evidence of HER3-mediated sig-
naling. This biomarker could be useful for predicting 
which cancers would benefit from anti-HER3 thera-
pies and as a pharmacodynamics marker for HER2 
or HER3-targeting therapies, in other words, for 
assessing the drugs’ efficacy and monitor their effect 
through time [33,40,52]. pHER3/HER3 ratio is pointed 
out as other promising pharmacodynamics marker [52]. 
Proximity-based immunoassays are being investigated 
as instruments to quantitatively measure HER3 acti-
vation in breast tumor samples [53] and may be useful 
tools if the discussed biomarkers reveal to be effective. 
As described for HER2, nuclear imaging methods are 
also a future possibility for detecting HER3-expressing 
neoplasias [54].
Although several targets are being studied and new 
drugs against HER2 and/or HER3 receptors are being 
tested, target populations that may benefit from these 
therapies are still to be found. Moreover, effective 
treatment-monitoring is not yet a reality. It is urgent 
that some biomarkers emerge as good predictors of 
response to help decision making during clinical trials 
and, maybe in the future, to be used in clinical prac-
tice, allowing an effective therapy for those patients 
who can benefit of it and less adverse events to those 
who cannot.
Targeting HER2
Trastuzumab is a humanized mAb that has high 
affinity for domain IV of the extracellular part of the 
HER2 receptor (Figure 2) [55]. The several mechanisms 
by which trastuzumab is believed to act include: pre-
vention of ligand-independent dimerization, induction 
of endocytotic destruction of the receptor, induction of 
antibody-dependent cellular cytotoxicity (ADCC) and 
inhibition of extracellular domain cleavage [55]. Trastu-
zumab efficiently disrupts the formation of ligand-
independent dimers but fails to block ligand-induced 
dimers [56].
The approval of trastuzumab for HER2-positive 
MBC in combination with chemotherapy was based in 
a clinical trial that demonstrated that, when compared 
with chemotherapy alone, the combination was associ-
ated with a higher rate of objective response (ORR; 50 
vs 32%; p < 0.001), a longer time to disease progression 
(TTP; 7.4 vs 4.6 months; p < 0.001), a longer duration 
of response (9.1 vs 6.1 months; p < 0.001) and a lon-
ger median overall survival (OS; 25.1 vs 20.3 months; 
p = 0.046) [57]. Trastuzumab is also approved for the 
treatment of HER2-overexpressing MBC without 
chemotherapy [58]. Therapeutic schemes hat include 
trastuzumab are the preferred first-line treatment for 
these cancers in Europe, however, in the US a dual 
HER2-targeting approach that combines trastuzumab 
and pertuzumab is preferred [59,60].
It is also established that continuing HER2-target-
ing even in HER2-positive MBC that progressed dur-
ing trastuzumab treatment is beneficial. Trastuzumab 
plus capecitabine is superior to capecitabine alone in 
these patients as it is associated with a significantly 
improved TTP (8.2 vs 5.6 months; p = 0.0338) and 
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ORR (48.1 vs 27.0%; p = 0.0115) and does not increase 
toxicity [61]. Hence, the continued use of trastuzumab 
plus chemotherapy is a second-line treatment for MBC 
(Table 1) [59,60].
The main concern regarding the use of trastuzumab 
is cardiac dysfunction. Hence, cardiac monitoring is 
recommended for patients receiving treatments with 
this mAb [60]. Despite this adverse event is potentially 
severe, it seems to be reversible with standard medical 
management in the majority of cases [57,62].
Lapatinib is an oral, TKI that reversibly competes 
with ATP for the ATP-binding site in HER2 and 
HER1 tyrosine kinases, downregulating these recep-
tors’ phosphorylation (Figure 2) [63]. It targets the 
intracellular domain of HER2 whereby it is capable 
of inhibiting p95HER2 activity [64]. Also, as it uses 
a different molecular pathway of interfering with this 
network, it is still effective against trastuzumab-resis-
tant BC cells [65]. The combination of lapatinib plus 
capecitabine has proven to be superior when compared 
with capecitabine alone in women with HER2-positive 
advanced or metastatic BC that progressed after treat-
ment with trastuzumab. TTP was shown to be signifi-
cantly improved (8.4 vs 4.4 months; p < 0.001) with-
out an increase in serious adverse events [66]. Thus, this 
combination is approved for tumors that progressed 
on/after trastuzumab-based therapies, constituting a 
second-line treatment in the metastatic setting in the 
US and in Europe (Table 1) [59,60].
Pertuzumab is a humanized mAb that binds to the 
subdomain II of the extracellular part of HER2, pre-
venting ligand-dependent dimerization and inducing 
ADCC (Figure 2) [67]. Hence, pertuzumab and trastu-
zumab exhibit complementary mechanisms of action 
and, when combined, act synergistically to inhibit BC 
cells survival [35]. Pertuzumab has been approved by 
the  US FDA and by the EMA but it is only used in 
combination with trastuzumab (Table 1). Combination 
of therapies will be discussed in more detail later on 
this article.
Ado-trastuzumab emtansine (T-DM1) is an anti-
body-drug conjugate incorporating trastuzumab and 
DM1, a microtubule-disrupting drug (Figure 2). DM1 
has the ability to be delivered directly in the intra-
Agent Molecular target and mechanism 
of action
Licensed indication (therapy line) 
or development status (NCT)
Efficacy
Trastuzumab HER2 (domain IV): prevents 
ligand-independent dimerization, 
induces HER2 endocytotic 
destruction, ADCC and inhibits 
HER2 cleavage
HER2-positive recurrent or MBC 
(first line)  
HER2-positive recurrent or MBC 
(second line)
T + CT vs CT [57]: ORR 50 vs 32% 
(p < 0.001); TTP 7.4 vs 4.6 months 
(p < 0.001); OS 25.1 vs 20.3 months 
(p = 0.046)  
T + C vs C [61]: ORR 48.1 vs 27.0% 
(p = 0.0115); TTP 8.2 vs 5.6 months 
(p = 0.0338); OS 25.5 vs 20.4 
months (p = 0.257)
Lapatinib HER1, HER2 TKI HER2-positive recurrent or MBC 
(second line)
L + C vs C [66]: ORR 22 vs 14% 
(p = 0.09); TTP 8.4 vs 4.4 months 
(p < 0.001)
Pertuzumab HER2 (domain II): inhibits 
dimerization, induces ADCC
Approved only in combination 
regimens (see Table 2)
 
T-DM1 HER2 (domain IV): all the referred 
for trastuzumab plus targeted 
delivery of an anti-microtubule 
agent
HER2-positive recurrent or MBC 
(second line)
T-DM1 vs L + C [68]: ORR 43.6 vs 
30.8% (p < 0.001); PFS 9.6 vs 6.4 
months (p < 0.001); OS 30.9 vs 25.1 
months (p < 0.001)
Neratinib HER1, HER2 TKI III (NCT01808573)  
II (NCT00915018)  
II (NCT01494662)
N (prior T) vs N (T-naive) [69]: ORR 
24 vs 56%; 16-week PFS 59 vs 78%; 
PFS 22.3 vs 39.6 weeks
Afatinib HER1, HER2 TKI II (NCT00431067) [70]  
III (NCT01125566)  
II (NCT01271725)  
II (NCT01441596)
A (single-arm) [70]: PFS 15.1 weeks 
OS 61.0 weeks
A: Afatinib; ADCC: Antibody-dependent cellular cytotoxicity; C: Capecitabine; CT: Chemotherapy; L: Lapatinib; MBC: Metastatic breast cancer; N: Neratinib; 
NCT: Clinicaltrials.gov identifier; ORR: Overall response rate; OS: Overall survival; PFS: Progression-free survival; T: Trastuzumab; TKI: Tyrosine kinase inhibitor; 
TTP: Time to tumor progression; T-DM1: Ado-trastuzumab emtansine.
Table 1. HER2-targeted drugs in single anti-HER2 therapies for the treatment of HER2-positive metastatic breast 
cancer.
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cellular compartment of HER2-overexpressing cells, 
which minimizes exposure of normal tissues and 
improves the therapeutic index. T-DM1 retains all 
the mechanisms of action of trastuzumab and is still 
active against heavily pretreated HER2-positive MBC, 
namely in cancers that progressed on trastuzumab 
[68]. Also, it seems to be the only drug that is still 
efficient even when oncogenic activations of PIK3CA 
are present [45]. When compared with lapatinib and 
capecitabine, as in the EMILIA study, T-DM1 signifi-
cantly improves ORR (43.6 vs 30.8%; p < 0.001), PFS 
(9.6 vs 6.4 months; p < 0.001) and OS (30.9 vs 25.1 
months; p < 0.001) with less toxicity (41 vs 57%) [68]. 
This drug was approved by the FDA and the EMA 
for use as a single agent in HER2-positive MBC that 
recurred after treatment with trastuzumab and a tax-
ane. It is the preferred second-line treatment for MBC 
in the US; however, its use is not contemplated in 
European guidelines yet (Table 1) [59,60].
Neratinib is an irreversible TKI of HER1, HER2 
and HER4 (Figure 2) [69] and appears to be active 
in cells with HER2 mutations that are resistant to 
lapatinib [17]. It is currently being tested in combi-
nation with paclitaxel as a first-line treatment for 
HER2-positive advanced BC (NCT00915018), with 
capecitabine as a second-line treatment for HER2-
positive MBC (NCT01808573) and as a single-agent 
for patients with HER2-positive BC and brain metas-
tases (NCT01494662). A Phase II trial compared the 
effect of this TKI in patients with advanced BC with 
and without prior trastuzumab treatment: 16-week 
PFS rates were 59 and 78%, PFS was 22.3 and 39.6 
weeks and ORR were 24 and 56%, respectively. This 
study demonstrated that neratinib is clinically active 
and reasonably well tolerated in patients that received 
prior trastuzumab treatment and in trastuzumab-naive 
patients (Table 1) [69].
Afatinib is also an irreversible TKI of HER1, 
HER2 and HER4 (Figure 2) [70]. It was studied as 
a single-agent in a Phase II trial in patients with 
HER2-positive MBC that progressed on trastuzumab 
(NCT00431067), where a PFS of 15.1 weeks (95% 
CI: 8.1–16.7) and an OS of 61.0 weeks (95% CI: 
56.7-not evaluable) were shown [70]. Afatinib is cur-
rently being tested in the Phase III trial LUX-Breast 1 
(NCT01125566) in combination with vinorelbine in 
patients with HER2-overexpressing MBC that failed 
prior treatment with trastuzumab. Also, two Phase II 
trials are evaluating afatinib for HER2-driven MBC: 
LUX-Breast 2 trial (NCT01271725), which is test-
ing afatinib alone and in combination with paclitaxel 
or vinorelbine in patients that failed HER2-targeted 
treatment in the neoadjuvant or adjuvant setting; and 
LUX-Breast 3 trial (NCT01441596), that is studying 
afatinib alone and in combination with vinorelbine in 
patients with progressive brain metastases after treat-
ment with trastuzumab and/or lapatinib (Table 1). 
This drug was approved by the FDA and the EMA but 
only for non-small-cell lung cancer.
Dual HER2-targeted approaches
Due to their complementary mechanisms of action, 
different strategies to combine trastuzumab and per-
tuzumab have been tested (Table 2). The combination 
of trastuzumab, pertuzumab and docetaxel or pacli-
taxel is currently the preferred first-line treatment for 
HER2-positive MBC in the US. In Europe, despite 
pertuzumab has been approved for MBC, this regi-
men is not yet part of the guidelines used [59,60]. The 
approval of pertuzumab in this therapeutic scheme fol-
lowed the results of Phase III CLEOPATRA, where 
the use of pertuzumab, trastuzumab and docetaxel 
compared with the use of placebo, trastuzumab and 
docetaxel showed a significant improvement in PFS 
(18.5 vs 12.4 months; HR 0.62; p < 0.001) and OS 
(not reached vs 37.6 months; HR 0.66; p = 0.0008) 
without an increase in cardiac toxic effects [37,67].
The combination of trastuzumab and lapatinib 
proved to be superior in terms of PFS (11.1 vs 8.1 weeks; 
HR 0.74; p = 0.011) and OS (14 vs 9.5 months; HR 
0.74; p = 0.026) in comparison with lapatinib alone in 
patients with HER2-positive trastuzumab-refractory 
MBC. This combination was found to have an accept-
able safety profile and offers a chemotherapy-free regi-
men [71]. Combined trastuzumab and lapatinib consti-
tutes a second-line treatment for recurrent or MBC in 
the US and, despite not being in European guidelines 
yet, it is approved by the EMA (Table 2) [59,60].
A single-arm Phase Ib/II trial (TDM4373g) stud-
ied T-DM1 and pertuzumab as a first and second-
line treatment in patients with HER2-overexpressing 
locally advanced or metastatic BC. An ORR of 57.1% 
(95% CI: 34.0–78.2%) in the first-line setting and 
of 34.8% (95% CI: 22.2–50.0%) in the refractory 
setting was obtained. The clinical benefit rate was 
61.9% (95% CI: 39.8–80.3%) and 45.7% (95% CI: 
30.9–60.2%), respectively. This trial showed that this 
combination is clinically active and has an acceptable 
safety and tolerability profile [72] and encouraged fur-
ther studies. The ongoing Phase III MARIANNE trial 
(NCT01120184) is studying T-DM1 plus pertuzumab 
versus T-DM1 versus trastuzumab plus a taxane as a 
first-line treatment for metastatic and locally advanced 
BC (Table 2).
A study in Phase I/II (NCT00398567) is evaluat-
ing the combination of trastuzumab and neratinib for 
patients with HER2-positive MBC that progressed 
on trastuzumab (Table 2). In preliminary results this 
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combination appeared to be generally well tolerated 
and clinically active (ORR 27% (95% CI: 13–46%); 
16-week PFS 47% (95% CI: 29–63%); PFS 19 weeks 
(95% CI: 15–32 weeks) [73].
Targeting HER3
Monoclonal antibodies
As HER3 is kinase impaired, targeting this receptor 
has been a challenge. The majority of drugs capable of 
effectively targeting HER3 are antibodies that bind 
to its extracellular domain, however, even among 
them, not all have revealed effective in HER2-ampli-
fied BC cell lines. In this article only anti-HER3 
antibodies included in clinical trials assessing their 
efficacy in patients with HER2-positive BC or that 
proved efficient in HER2-positive BC cell lines will 
be discussed (Table 3).
Patritumab (U3-1287 or AMG-888), a fully human-
ized mAb, was the first HER3-targeted antibody. It 
binds to the extracellular domain of HER3, promoting 
its internalization and inhibiting its basal and ligand-
induced signaling (Figure 2) [74]. In a Phase I study in 
advanced solid tumors (NCT00730470) a favorable 
safety profile and preliminary evidence of antitumor 
activity were observed [74], encouraging studies that are 
currently assessing this drug’s activity in combination 
with anti-HER2 drugs (Table 4).
Another antibody against HER3 is the human-
ized mAb AV-203 that prevents ligands to bind with 
HER3 and induces receptor degradation (Figure 2). It 
was shown that this antibody potently inhibits both 
ligand-dependent and ligand-independent activation 
of HER3 and also inhibits tumor growth in human 
BC representing xenografts. AV-203 was able to restore 
sensitivity to lapatinib in a HER2-positive BC model, 
suggesting that its combination with HER2-targeted 
therapies could prevent the emergence of HER3-
induced resistance [75]. Thus, AV-203 is currently 
being evaluated in a Phase I study for the treatment of 
advanced solid tumors (NCT01603979).
LJM716 is a fully humanized mAb that possesses 
a novel mechanism of action: it binds to domains II 
and IV of HER3, locking it in its inactive conforma-
tion (Figure 2). It is capable of inhibiting ligand-depen-
dent and ligand-independent HER3 activation and 
HER2-overexpressing cancer cells proliferation. Also, 
it revealed to be active as a single-agent in tumor xeno-
grafts and demonstrated a synergic antitumor effect 
when combined with trastuzumab [76]. This drug is 
being tested in a Phase I study in HER2-overexpressing 
MBC (NCT01598077).
RG7116 (GE-huMab-HER3 or RO5479599) binds 
to the domain I of HER3, preventing HRG-binding 
to this receptor and downregulating its cell surface 
expression (Figure 2). Also, as it is a glycol-engineered 
antibody, it is a more potent activator of ADCC than 
conventional antibodies [77]. In a preclinical study, this 
mAb activity showed to be increased in combination 
with pertuzumab [77]. A Phase I clinical trial is testing 
this drug as a single-agent and in combination with 
anti-HER1 agents (NCT01482377). In a preliminary 
analysis, RG7116 monotherapy was well tolerated and 
showed signs of clinical activity [78].
Bispecific antibody
Bispecific antibodies started to be designed based on 
the hypothesis that co-targeting two tumor-associated 
antigens would increase tumor-targeting specificity 
Combination of anti-HER2 
agents (therapy line)
Efficacy or primary end point Clinical trial 
(reference or NCT)
Licensed indications or 
development status
T + P + docetaxel (first line) T + P + docetaxel vs T + docetaxel: PFS 
18.5 vs 12.4 months (HR 0.62; p < 0.001); 
OS not reached vs 37.6 months (HR 0.66; 
p = 0.0008); ORR 80.2 vs 69.3% (p = 0.001)
CLEOPATRA [37,67] HER2-positive recurrent 
or MBC
T + L (second line) T + L vs L: PFS 11.1 vs 8.1 weeks (HR 0.74; 
p = 0.011); OS 14 vs 9.5 months (HR 0.74; 
p = 0.026)
EGF104900 [71] HER2-positive recurrent 
or MBC
T-DM1 + P (first line) PFS AEs MARIANNE 
(NCT01120184)
Phase III
T + N (second line) ORR 27% (95% CI: 13–46%)†; PFS 16-week 
47% (95% CI: 29–63%)†; PFS 19 weeks 
(95% CI: 15–32 weeks)†
(NCT00398567) [73] Phase I/II
For each combination of anti-HER2 agents only the clinical trial with the highest development status was considered in this table.
†Preliminary results.
AE: Adverse event; HR: Hazard ratio; L: Lapatinib; MBC: Metastatic breast cancer; N: Neratinib; NCT: Clinicaltrials.gov identifier; ORR: Overall response rate; 
OS: Overall survival; P: Pertuzumab; PFS: Progression-free survival; T: Trastuzumab; T-DM1: Ado-trastuzumab emtansine.
Table 2. Dual HER2-targeted approaches for the treatment of HER2-positive metastatic breast cancer.
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and decrease the toxic effect on normal tissues. In fact, 
MM-111 (ALM), an antibody that targets both HER2 
and HER3, exhibits selective targeting of tumor cells that 
co-express these receptors [79]. MM-111 binds to HER2 
and subsequently to HER3, forming a trimeric complex 
and blocking its ligand-induced activation (Figure 2). 
In preclinical studies, the inhibition of ligand-mediated 
HER3 phosphorylation was greater with MM-111 than 
with pertuzumab and, when combined with trastu-
zumab, MM-111 is more effective at inhibiting tumor 
cell growth than trastuzumab plus pertuzumab. Also, 
MM-111 showed to be more effective at blocking 
ligand-induced HER3 phosphorylation than lapatinib 
and proved to increase PIK3-AKT pathway suppres-
sion when added to lapatinib [80]. Hence, this antibody 
was studied in HER2-positive cancers in a Phase I trial 
(NCT00911898) revealing to be well tolerated (Table 3) 
[81]. Currently, it’s being studied in combination with 
several anti-HER2 regimens (Table 4).
Histone deacetylase inhibitor
Entinostat (SNDX-275) is a histone deacetylase inhibi-
tor (HDACi) that dual-targets HER2 and HER3. It is 
believed that its effect is due to an ability to induce the 
transcription of microRNAs that silence the expression 
of HER2 and HER3 (Figure 2) [82]. It acts preferentially 
Agent Molecular target Mechanism of action Development status (NCT)
Patritumab (U3-1287 or 
AMG-888)
HER3 (ECD) Promotes HER3 internalization and inhibits 
basal and ligand-induced signaling
I (NCT00730470) [74]
AV-203 HER3 (ECD) Prevents ligand binding, inhibits ligand-
dependent and -independent activation 
and induces HER3 degradation
I (NCT01603979)
LJM716 HER3 (domains II 
and IV)
Locks HER3 in its inactive conformation 
and inhibits ligand-dependent and 
-independent signaling
I (NCT01598077)
RG7116 (GE-huMab-HER3 
or RO5479599)
HER3 (domain I) Prevents HRG binding, reduces HER3 cell 
surface expression and mediates enhanced 
ADCC
I (NCT01482377) [78]
MM-111 (ALM) HER2 and HER3 (ECD) Forms a trimeric complex with HER2 and 
HER3, blocking HER3 binding with HRG
I (NCT00911898) [81]
Entinostat (SNDX-275) HDACs Inhibits the HDACs inducing the 
transcription of miRNAs that silence the 
expression of HER2 and HER3
I (NCT00020579) [85]
ADCC: Antibody-dependent cellular cytotoxicity; ECD: Extracellular domain; HDAC: Histone deacetylase; NCT: Clinicaltrials.gov identifier.
Table 3. Drugs targeting HER3 and their mechanism of action.
Combination of anti-HER2 and 
anti-HER3 agents
Setting (therapy line) Primary end 
point
Development status 
(NCT)
T + patritumab + paclitaxel HER2-positive MBC 
(first line)
DLT, PFS Ib/II (NCT01512199)
MM-111 + T HER2-positive ABC 
(second line)
Safety I (NCT01097460)
MM-111 + T + CT MM-111 + T ± L HER2-positive AST 
(second line)
Safety, DLT, MTD I (NCT013047849)
LJM716 + T HER2-positive MBC 
(second line)
DLT I (NCT01602406)
RG7116 + T + paclitaxel HER2-positive MBC 
expressing HER3
DLT, AEs, PK, 
HAHAs
I (NCT01918254)
Entinostat + T + L HER2-positive MBC 
(second line)
RP2D I (NCT01434303)
ABC: Advanced breast cancer; AE: Adverse event; AST: Advanced solid tumors; CT: Chemotherapy; DLT: Dose limiting toxicity; 
HAHA: Human anti-human antibody; L: Lapatinib; MBC: Metastatic breast cancer; MTD: Maximum tolerated dose; NCT: Clinicaltrials.gov 
identifier; PFS: Progression-free survival; PK: Pharmacokinetics; RP2D: Recommended Phase II dose; T: Trastuzumab.
Table 4. Dual targeting: HER2 and HER3.
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in HER2-overexpressing cell lines inhibiting down-
stream signaling and reducing the levels of pHER2, 
pHER3, pAKT and pMAPK [83]. This HDACi showed 
to enhance trastuzumab-mediated growth inhibition 
in trastuzumab-sensitive and resistant BC cells that 
overexpressed HER2 (Table 3) [84]. Entinostat revealed 
to be well tolerated in a Phase I study (NCT00020579) 
[85] and is currently being studied in combination with 
HER2-inhibitors (Table 4).
As HER2-overexpression is the main driver of 
HER2-positive BC, the greater promise regarding 
HER3-targeted drugs is not their action as single-agents 
but the potential of dual targeting HER2 and HER3 to 
potentiate the inhibition of tumor growth and reduce 
the acquisition of resistance. Hence, several dual target-
ing strategies with HER2 and HER3-targeted drugs are 
being evaluated. Clinical trials currently evaluating dual 
HER2/HER3-targeted strategies in HER2-positive BC 
are summarized in Table 4.
Conclusion
As knowledge about this type of cancer evolved, 
remarkable progress was made that significantly 
improved its prognosis: HER2-targeted therapies and 
strategies to double-target HER2 are two great exam-
ples of success regarding HER2-positive BC. Still, 
overcoming resistance to targeted therapies in HER2-
positive MBC remains an incredible challenge. The 
ErbB network is now recognized as interdependent 
and resilient and as having several mechanisms con-
Executive summary
ErbB family
•	 When overexpressed, this family is responsible for unregulated cell division, apoptosis, migration, adhesion 
and differentiation: all processes leading to tumorigenesis.
•	 HER3 is a particular receptor as it is kinase-impaired and capable of the strongest activation of the PI3K/AKT 
pathway.
ErbB family in HER2-positive breast cancer
•	 HER2 overexpression is an early event in neoplastic transformation. Nevertheless, HER2 interactions with other 
ErbB receptors have a crucial role in neoplastic progression.
•	 HER2/HER3 dimerization is required for full signaling potential and this dimer is the key oncogenic unit.
Targeting HER family
•	 Resistance to targeted therapies remains an enormous challenge. When inhibiting the PI3K/AKT pathway (as 
with anti-HER2 drugs), a negative feedback response leads to a rebound in HER3 activity, which is one of the 
main mechanisms contributing to resistance.
•	 The combination of targeted therapies is superior to single-agent strategies. Strategies double-targeting HER2 
proved to improve these tumors’ outcome, however, they are still unable to fully block this feedback response. 
Strategies simultaneously inhibiting HER2 and other targets are being thoroughly studied.
Biomarkers
•	 HER2 overexpression as defined by FISH or immunohistochemistry remains the only biomarker approved to 
guide HER2-targeted therapy.
•	 pHER3 is one of the molecular markers believed to have the greatest potential both to monitor treatment 
response to anti-HER2 and/or anti-HER3 drugs and to predict which patients might benefit from HER3-
targeted therapy.
•	 It is urgent that some biomarkers emerge for a better prediction and monitoring of anti-HER2 therapies’ 
effect and to guide decision making in clinical trials testing HER3-targeted drugs.
Targeting HER2
•	 Trastuzumab, lapatinib and T-DM1 are approved as single anti-HER2 agents for the treatment of HER2-positive 
metastatic breast cancer (MBC). Strategies double-targeting HER2 in MBC with trastuzumab plus pertuzumab 
or trastuzumab plus lapatinib are also approved.
•	 Dual targeting approaches enhance progression-free survival and overall survival but still cannot avoid tumor 
progression.
Targeting HER3
•	 Targeting this receptor is a great promise to further inhibit neoplastic progression. Monoclonal antibodies, 
bispecific antibodies and one inhibitor of the histone deacetylases are being studied in clinical trials. 
Combinations of these therapies with anti-HER2 drugs are also being evaluated.
Conclusion
•	 Further studies are required for a realistic understanding of these drugs’ utility, to set the optimal 
combinations between them and to establish novel biomarkers to guide their use.
•	 This new approach is hoped to become another step toward individualized and enhanced treatment for 
patients with HER2-positive MBC.
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tributing to the acquisition of resistance [33]. Among 
them HER3 has emerged as a potential target. HER3 
possess an intracellular domain that is at the same 
time kinase-impaired [13] and capable of the strongest 
activation of the PI3K/AKT pathway [9]. HER3 is 
now established as a crucial coreceptor for treatment 
response and acquired resistance. Therefore, HER3-
targeted drugs and the association between them and 
anti-HER2 therapies are currently in clinical devel-
opment. In spite of being in early stages of develop-
ment, these combinations showed great potential in 
preclinical studies and are believed to be capable of 
improving HER2-positive MBC prognosis [80].
Biomarkers to predict and monitor the response to 
anti-HER2 therapies and to predict which patients 
may benefit from HER3-targeted agents in clinical tri-
als are of utmost importance. Besides emerging as a 
potential target, HER3 has also emerged as a promis-
ing biomarker. Despite no molecular markers besides 
HER2 overexpression have been approved, biomark-
ers such as pHER3, ERBB3 mRNA, p95HER2 and 
PIK3CA-activating mutations, amid others, are being 
studied.
Future perspective
The progress of targeted therapies directed against 
HER2 has been astonishing. Nevertheless, there is 
still room for improvement. A better understanding 
of the optimal use of the combinations of anti-HER2 
drugs and of the potential biomarkers is needed. 
Regarding this last subject, pHER3 has been one 
of the greatest promises to monitor the response to 
HER2 or HER3-targeted therapies and to predict 
which patients would benefit from HER3-targeted 
treatment [33,40,52]. It is expected that future studies 
can clarify its role.
When it comes to HER3-targeted therapy, there is 
still a long way to go before some of these possibilities 
become real treatment options in clinical practice. It is 
predicted that in the next few years there will be a more 
realistic awareness of the effect and utility of the avail-
able drugs and of the optimal combinations between 
them. The only ongoing Phase II study assessing a 
combination between HER2 and HER3-targeted 
therapies (NCT01512199) is estimated to be complete 
in the present year. Also, if these drugs actually prove 
to be efficient, we can anticipate that the molecular 
markers to guide and monitor its use will be assessed 
more extensively in future biomarkers analysis.
Individualized therapies are the ultimate goal for can-
cer treatment. As the combination of targeted therapies 
has been proving to be a successful strategy and HER3 
is established as a pivotal oncogenic receptor in the ErbB 
network, this new approach is hoped to become another 
step toward individualized and enhanced treatment for 
patients with HER2-positive MBC.
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